Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Trial of SB12 vs Soliris in Paroxysmal Nocturnal Haemoglobinuria
2018-002857-31Phase 3Active
- Sponsor
- Samsung Bioepis
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of SB12 in paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by Samsung Bioepis. Primary endpoint: LDH level at Week 26. Started Jul 2022; status: active.
02
Drugs
SB12
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2018-002857-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002857-31.